Transthyretin cardiomyopathy – diagnosis and therapeutic options
Annales Academiae Medicae Silesiensis · 29.05.2026
DOI: 10.18794/aams/220040 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annales Academiae Medicae Silesiensis, online erschienen am 29.05.2026. Verfasst von Alicja Pawlus und 2 weiteren Autor:innen. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-SA 4.0).
Abstract (Originalsprache)
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a rare but increasingly recognized cause of heart failure. ATTR-CM results from the deposition of misfolded transthyretin (TTR) protein fibrils in the extracellular matrix. Two main forms of ATTR are distinguished: hereditary (hATTR) and wild-type (wtATTR). The diagnostic gold standard has shifted from invasive biopsy toward a non-invasive algorithm, which includes laboratory tests, echocardiography, cardiac magnetic resonance, and scintigraphy. Contemporary disease-modifying therapeutic strategies – transthyretis stabilizers (tafamidis, acoramidis) and gene-silencing drugs (vutrisiran, patisiran) significantly improve the prognosis and functional capacity of patients with ATTR-CM.
Zitieren
APA
Pawlus, A., Kolebacz, K., & Średniawa, B. (2026). Transthyretin cardiomyopathy – diagnosis and therapeutic options. Annales Academiae Medicae Silesiensis. https://doi.org/10.18794/aams/220040
Vancouver
Pawlus A, Kolebacz K, Średniawa B. Transthyretin cardiomyopathy – diagnosis and therapeutic options. Annales Academiae Medicae Silesiensis. 2026. doi:10.18794/aams/220040
BibTeX
@article{Pawlus2026,
author = {Pawlus, Alicja and Kolebacz, Kacper and Średniawa, Beata},
title = {Transthyretin cardiomyopathy – diagnosis and therapeutic options},
journal = {Annales Academiae Medicae Silesiensis},
year = {2026},
doi = {10.18794/aams/220040}
}
EUVIMED